Identification and Characterization of a Novel Nanobody Against Human CTGF to Reveal Its Antifibrotic Effect in an in vitro Model of Liver Fibrosis

Rong Liu1 Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, 200072, People’s Republic of China

Min Zhu2 Shanghai Novamab Biopharmaceuticals Co., Ltd, Shanghai, 201318, People’s Republic of China

Jiaojiao Chen3 Department of Gastroenterology, Shanghai Fourth People’s Hospital, Tongji University School of Medicine, Shanghai, 200434, People’s Republic of China

Junwei Gai2 Shanghai Novamab Biopharmaceuticals Co., Ltd, Shanghai, 201318, People’s Republic of China

Jing Huang2 Shanghai Novamab Biopharmaceuticals Co., Ltd, Shanghai, 201318, People’s Republic of China

Yingqun Zhou1 Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, 200072, People’s Republic of China

Yakun Wan2 Shanghai Novamab Biopharmaceuticals Co., Ltd, Shanghai, 201318, People’s Republic of China

Chuantao Tu4 Department of Gastroenterology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of ChinaCorrespondence[email protected] [email protected]

show all

Identification and Characterization of a Novel Nanobody Against Human CTGF to Reveal Its Antifibrotic Effect in an in vitro Model of Liver Fibrosis

Articles from other publishers (1)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Identification and Characterization of a Novel Nanobody Against Human CTGF to Reveal Its Antifibrotic Effect in an in vitro Model of Liver Fibrosis

Citations (1)

Articles from other publishers (1)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date